分组1 - Alector reported a quarterly loss of $0.34 per share, better than the Zacks Consensus Estimate of a loss of $0.39, representing an earnings surprise of +13.71% [1] - The company posted revenues of $6.24 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 103.43%, compared to $54.24 million in the same quarter last year [2] - Alector has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times [2] 分组2 - Alector shares have increased by approximately 40.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on $3 million in revenues, and for the current fiscal year, it is -$1.19 on $12 million in revenues [7] - The Medical - Biomedical and Genetics industry, to which Alector belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38792 Alector, Inc. (Exact name of Registrant as specified in its Charter) Delaware 001-38792 82-2933343 (State or other jurisdiction of ...

Exhibit 99.1 Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer's Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer's Disease) Independent interim futility analysi ...

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer’s Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer’s Disease) Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer’s disease expected in the first h ...

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a corporate presentation at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 pm ET. A live webcast of the corporate presentation will be available on the “Events & Presentations” page within the Inv ...

Core Viewpoint - Alector, Inc. has faced disappointment following the announcement of mixed topline results from its Phase 3 INFRONT-3 trial, which evaluated the efficacy of latozinemab in treating frontotemporal dementia due to a gene mutation [2][4][5] Group 1: Trial Results - The Phase 3 INFRONT-3 trial aimed to evaluate the efficacy of latozinemab in slowing disease progression in patients with frontotemporal dementia due to a progranulin gene mutation, enrolling 119 patients with a mean age of 62.1 years [3] - The trial had two co-primary endpoints: biomarker response, which was met, and clinical response, which was not met, as the trial failed to achieve its efficacy-based co-primary endpoint of slowing FTD-GRN progression [4] Group 2: Investor Reaction - Following the release of the mixed topline results, analysts expressed disappointment and subsequently downgraded Alector's stock [5]

Core Insights - Alector Inc. (ALEC) has experienced significant stock volatility, particularly influenced by the progress of its drug Latozinemab through the pipeline and a recent negative data readout in late October [1] Company Overview - Alector is focused on biotechnology, specifically in developing innovative therapies that utilize novel mechanisms of action and first-in-class therapies [1] - The company aims to reshape treatment paradigms through platform technologies [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis in the biotech sector [1] - The analyst has been active in the investing space for five years, with a focus on biotech equity analysis for the last four years [1] Research Approach - The research emphasizes evaluating the scientific basis of drug candidates, the competitive landscape, clinical trial design, and market opportunities while balancing financial fundamentals and valuation [1] - The goal is to provide insights that help investors understand both opportunities and risks in the biotech sector [1]

Core Insights - Alector, Inc. has appointed Neil Berkley as Chief Financial Officer (CFO), effective December 10, 2025, while he continues to serve as Chief Business Officer (CBO) [1][2] Company Overview - Alector is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, utilizing genetics, immunology, and neuroscience [3] - The company aims to address conditions such as Alzheimer's disease, Parkinson's disease, and frontotemporal dementia through its innovative product candidates [3] - Alector is developing the Alector Brain Carrier (ABC) platform to enhance therapeutic delivery across the blood-brain barrier, aiming for improved patient outcomes and cost reduction [3] Leadership Insights - Neil Berkley has over two decades of experience in corporate strategy, finance, business development, and operations within the biotech sector [2] - His leadership has been pivotal in advancing Alector's strategic priorities and strengthening partnerships since joining the company in 2024 [2] - Berkley's background includes founding two companies and serving on multiple biotech boards, showcasing his extensive industry experience [2]

Group 1 - The article does not provide any specific content related to company or industry analysis [1]

Summary of Alector Therapeutics Conference Call Company Overview - Alector is focused on neurodegeneration, developing therapeutics for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders [5][6][24] - The company has five drugs in clinical trials and multiple preclinical programs utilizing proprietary blood-brain barrier technology [5][6] Clinical Programs and Pipeline - **Progranulin-elevating drug**: In collaboration with GSK, targeting Alzheimer's disease with an interim analysis expected in the first half of next year [5][6] - **Anti-amyloid beta antibody**: Expected to enter the clinic next year, leveraging blood-brain barrier technology for enhanced delivery [6][10] - **GCase enzyme replacement therapy**: Targeting Parkinson's disease and Lewy body dementia, with over 10% of Parkinson's patients linked to loss of function mutations in this enzyme [6][36] - **siRNA programs**: Targeting Tau, alpha-synuclein, and NLRP3, aiming for safer and more effective delivery to the brain [6][7][45] Blood-Brain Barrier Technology - Alector's technology allows for the delivery of large molecules to the brain at 10- to 50-fold higher concentrations, enhancing efficacy and safety [9][10] - The use of transferrin technology as a "Trojan horse" to transport drugs across the blood-brain barrier is a key differentiator [12][13] - Alector claims to achieve 10-12 fold higher concentrations of drugs in the brain compared to competitors, potentially allowing for lower doses and subcutaneous delivery [14][24] Competitive Landscape - Current anti-amyloid beta drugs (e.g., lecanemab, aducanumab) show modest clinical benefits (25%-30% slowdown in cognitive decline) but have significant adverse effects [22][23] - Alector's anti-amyloid beta drug aims to reduce adverse effects like ARIA (e.g., meningoencephalitis) and improve patient compliance through subcutaneous delivery [24][25] AL137 and AL101 Programs - **AL137**: Lead antibody with brain penetration 4-12 times higher than competitors, targeting subcutaneous delivery [28][29] - **AL101**: In partnership with GSK, focusing on amyloid beta removal and minimal ARIA, with interim analysis expected in the first half of 2026 [49][50] Financial Position - Alector has approximately $300 million in cash, providing a runway through 2027 to support multiple clinical programs and advance the ABC platform [54][58] Key Takeaways - Alector is positioned to potentially revolutionize treatment for neurodegenerative diseases through innovative drug delivery technologies and a robust pipeline of therapeutics [10][24] - The company is focused on addressing the limitations of existing therapies, particularly in terms of safety and delivery methods, which could enhance patient compliance and treatment outcomes [25][45]